From GlobeNewswire: 2024-11-15 09:00:00

The DNA Synthesis Market, valued at $3.59 billion in 2023, is projected to reach $15.48 billion by 2032, with a 17.66% CAGR. Advancements in genomics research and therapeutic DNA applications are driving growth, with DNA synthesis technology playing a crucial role in scientific fields like synthetic biology and bioengineering.

Key companies in the DNA synthesis market include Thermo Fisher Scientific, Twist Bioscience Corporation, and Eurofins Scientific. Collaborations between technology firms and biotech companies are enhancing DNA synthesis methodologies, expanding applications in healthcare and beyond. Market players are investing heavily in R&D to meet the demand for high-precision genetic engineering tools and customized genetic materials.

Oligonucleotide synthesis dominated the DNA synthesis market in 2023, driven by genomics research and the increasing focus on genetic disorders. The gene synthesis segment is projected to achieve a 16.7% CAGR, playing a vital role in gene therapy approaches. The research and development segment accounted for the largest market share due to rising global initiatives in synthetic biology and genomics.

North America held the dominant position in the DNA synthesis market in 2023, benefiting from key biotech companies, research funding, and advanced healthcare infrastructure. The market is experiencing robust demand driven by breakthroughs in personalized medicine, biopharmaceuticals, and genome editing. Companies are expanding product portfolios and forming collaborations to deliver advanced DNA synthesis solutions. North America is a hub for DNA synthesis, with companies like Thermo Fisher Scientific and Twist Bioscience leading the way. R&D activities in the region are driving innovations in genomics and personalized medicine. In Asia-Pacific, countries like China and Japan are investing in biotechnological research, fueling the growth of the DNA synthesis market.

Recent developments include Molecular Assemblies launching a Partnering Program and QIAGEN collaborating with Element Biosciences. Eurofins BioPharma expanded its facility to meet rising demand, and TECAN partnered with Element Biosciences for a comprehensive NGS solution. These advancements highlight the crucial role of DNA synthesis in genetic research and therapeutics.

The DNA synthesis market is projected to grow significantly, with detailed insights and trends reporting on genetic disorders, application trends, and research spending by region. The competitive landscape includes major companies and market share analysis. With a focus on segmentation by service, application, and end-user, the market is poised for continued expansion and innovation.



Read more at GlobeNewswire: DNA Synthesis Market to Reach USD 15.48 Billion by 2032